Endotracheal cuff and technique for using the same

Information

  • Patent Grant
  • 10485942
  • Patent Number
    10,485,942
  • Date Filed
    Tuesday, March 1, 2016
    8 years ago
  • Date Issued
    Tuesday, November 26, 2019
    4 years ago
Abstract
An inflatable balloon cuff may be adapted to seal a patient's trachea when associated with an endotracheal tube. Configurations of these cuffs that include tapered regions with certain characteristics, such as cuff wall diameter and thickness, may provide improved sealing of the trachea.
Description
BACKGROUND OF THE INVENTION

1. Field of the Invention


The present invention relates to medical devices, and more particularly, to airway products, such as tracheal tubes and cuffs.


2. Description of the Related Art


This section is intended to introduce the reader to various aspects of art that may be related to various aspects of the present invention, which are described and/or claimed below. This discussion is believed to be helpful in providing the reader with background information to facilitate a better understanding of the various aspects of the present invention. Accordingly, it should be understood that these statements are to be read in this light, and not as admissions of prior art.


In the course of treating a patient, a tube or other medical device may be used to control the flow of air, food, fluids, or other substances into the patient. For example, medical devices such as tracheal tubes may be used to control the flow of one or more substances into or out of a patient. In many instances it is desirable to provide a seal between the outside of the tube or device and the interior of the passage in which the tube or device is inserted. In this way, substances can only flow through the passage via the tube or other medical device, allowing a medical practitioner to maintain control over the type and amount of substances flowing into and out of the patient.


For example, tracheal tubes may be used to control the flow of air or other gases through a patient's trachea. Such tracheal tubes may include endotracheal (ET) tubes, tracheostomy tubes, or transtracheal tubes. To seal these types of tracheal tubes, an inflatable cuff may be associated with these tubes. When inflated, the cuff generally expands into the surrounding trachea to seal the tracheal passage around the tube.


However, to fit a range of trachea anatomies and to provide low intra cuff pressure, cuff diameters are usually about one and a half times the diameter of the average trachea. Therefore, when inserted in an average-sized trachea, such a cuff is unable to fully expand and will fold in on itself within the trachea. These folds may serve as leak paths that allow mucosal secretions to flow past the cuff and enter the lung.


SUMMARY

Certain aspects commensurate in scope with the originally claimed invention are set forth below. It should be understood that these aspects are presented merely to provide the reader with a brief summary of certain forms the invention might take and that these aspects are not intended to limit the scope of the invention. Indeed, the invention may encompass a variety of aspects that may not be set forth below.


There is provided an inflatable balloon cuff that includes a proximal opening and a distal opening in a wall of the balloon cuff; and a tapered section along at least 50% of the length along an axis of the inflated balloon cuff, wherein the tapered section comprises a taper angle of at least 15 degrees, measured as an included angle of at least a portion of the tapered section and an imaginary axis connecting the proximal opening and the distal opening.


There is also provided a method of manufacturing an inflatable balloon cuff that includes providing a proximal opening and a distal opening in a wall of the balloon cuff; and providing a tapered section along at least 50% of the length along an axis of the inflated balloon cuff, wherein the tapered section comprises a taper angle of at least 15 degrees, measured as an included angle of at least a portion of the tapered section and an imaginary axis connecting the proximal opening and the distal opening.


There is also provided an inflatable balloon cuff that includes a tapered section, wherein a balloon wall of the tapered section is of continuously varying thickness along the tapered section such that the balloon wall at the widest point of the tapered section is thinner than the balloon wall at the narrowest point of the tapered section.


There is also provided a method of manufacturing an inflatable balloon cuff that includes providing an inflatable balloon cuff having a tapered section, wherein a balloon wall of the tapered section is of continuously varying thickness along the tapered section such that the balloon wall at the widest point of the tapered section is thinner than the balloon wall at the narrowest point of the tapered section.


There is also provided an inflatable balloon cuff that includes a tapered section, wherein at least a portion of the tapered section is adapted to form a wrinkle-free band against a patient's tracheal wall when inflated.


There is also provided a method of manufacturing an inflatable balloon cuff that includes providing an inflatable balloon cuff having a tapered section, wherein at least a portion of the tapered section is adapted to form a wrinkle-free band against a patient's tracheal wall when inflated.


There is also provided an inflatable balloon cuff that includes a tapered section comprising at least a portion of the balloon cuff, wherein at least a portion of the balloon walls in the tapered section are less than 60 microns in thickness.


There is also provided a method of manufacturing an inflatable balloon cuff that includes providing an inflatable balloon cuff having a tapered section comprising at least a portion of the balloon cuff, wherein at least a portion of the balloon walls in the tapered section are less than 60 microns in thickness.


There is also provided an inflatable balloon cuff that includes a proximal opening and a distal opening in a wall of the balloon cuff; a first tapered section along an imaginary axis connecting the proximal opening and the distal opening of the inflated balloon cuff; and a second tapered section along the imaginary axis connecting the proximal opening and the distal opening.


There is also provided an inflatable balloon cuff that includes a tapered section, wherein a balloon wall of the tapered section is of constant along the tapered section.





BRIEF DESCRIPTION OF THE DRAWINGS

Advantages of the invention may become apparent upon reading the following detailed description and upon reference to the drawings in which:



FIG. 1 illustrates an endotracheal tube with an inflatable balloon cuff in accordance with aspects of the present technique;



FIG. 2 illustrates the inflatable balloon cuff of the present techniques inserted into a patient's trachea;



FIG. 3 illustrates three different regions of the balloon cuff of the present techniques after insertion into a patient's trachea;



FIG. 4 is a top view of the wrinkled region of the balloon cuff of FIG. 3;



FIG. 5 is a top view of the wrinkleless band region of the balloon cuff of FIG. 3;



FIG. 6 is a top view of the minimal contact region of the balloon cuff of FIG. 3;



FIG. 7 illustrates an alternate configuration of the balloon cuff of the present techniques in which the cuff tapers towards the proximal end of the conduit;



FIG. 8 illustrates an alternate configuration of the balloon cuff of the present techniques having a generally hourglass configuration;



FIG. 9 illustrates an alternate configuration of the balloon cuff of the present techniques having a generally diamond-like configuration;



FIG. 10 is a flowchart depicting a blowmolding method of manufacturing a balloon cuff of the present techniques; and



FIG. 11 illustrates a balloon cuff of the present techniques with an antimicrobial layer.





DETAILED DESCRIPTION OF SPECIFIC EMBODIMENTS

One or more specific embodiments of the present invention will be described below. In an effort to provide a concise description of these embodiments, not all features of an actual implementation are described in the specification. It should be appreciated that in the development of any such actual implementation, as in any engineering or design project, numerous implementation-specific decisions must be made to achieve the developers' specific goals, such as compliance with system-related and business-related constraints, which may vary from one implementation to another. Moreover, it should be appreciated that such a development effort might be complex and time consuming, but would nevertheless be a routine undertaking of design, fabrication, and manufacture for those of ordinary skill having the benefit of this disclosure.


It is desirable to provide a medical balloon, such as an endotracheal cuff or other medical device, which may substantially seal the passage in which the cuff is inserted so that mechanical ventilation can be used to introduce air, oxygen, or medications into the lungs. In accordance with some aspects of the present technique, a medical balloon with a tapered shape is provided that is adapted to be used with an endotracheal tube or device.


The tapered balloon cuffs provided herein may provide advantages over a typical cuff. A typical inflatable cuff generally assumes a cylindrical or barrel shape when inflated that may include short tapered or partially tapered sections designed to connect the ends of the cuff to a narrower object, such as an endotracheal tube. Thus, a generally cylindrical cuff has a constant diameter along most of its length when fully inflated. This diameter is typically larger than the size of the tracheal passage. Therefore, when a typical cylindrical cuff is inserted into a patient's trachea and inflated, the cuff walls of the cylinder are unable to inflate to their maximum diameter and may fold in on themselves, which may cause wrinkles and leak paths to form.


A tapered cuff provides an improved seal against a patient's passage. Tapered cuffs include at least one section with a tapered shape. The tapered section includes a section that comes into direct contact with a patient's trachea. It should be understood that, in certain embodiments, the tapered section may be only a portion of the entire cuff. The tapered shape of the cuffs as provided herein results in the cuff displaying a range of inflated cuff diameters along the axis of the patient's passage. This range of cuff diameters results in at least one region along the inflated cuff that is substantially equal in diameter to a patient's trachea. The portion of the tapered cuff with a diameter that is substantially sized to the diameter of the trachea provides a relatively higher quality seal against the trachea that is substantially wrinkle-free.


The tapered shape of the cuffs as provided herein may be characterized by the cuff diameters at both ends of the taper. For example, the tapered shape may be described by providing the cuff diameter at the widest point of the taper as well as the cuff diameter at a narrower point. It should be understood that cuff diameters may be measured when the cuff is fully inflated while not inserted in a patient trachea along an axis that is substantially orthogonal to the axis of the endotracheal tube. A cuff diameter may be measured from cuff wall to cuff wall, either exterior wall to exterior wall or interior wall to interior wall. In certain embodiments, the taper may range from two times the size of an average trachea at the widest point to half the size of the average trachea or smaller at the narrowest part of the taper. It should be understood that an average trachea size may be an adult male or female average size that is based on height and weight, or a child average size. For example, an adult trachea may range in size from 14 mm to 27 mm, with the average being around 20 mm. Women typically use a size 7.0 to 7.5 endotracheal tube, while men may use a size 7.5 to 8.0 endotracheal tube. The size of the tube typically refers to the inside diameter of the main airway tube. In specific embodiments, the tapered region may narrow from a widest cuff diameter of 1.355 inches to a narrower diameter of 0.65 inches or smaller. It is envisioned that a single cuff may be designed to accommodate a wide variety of tracheal sizes along a single taper. Thus, a further advantage of a tapered cuff may be its adaptability to patients of a variety of sizes. In one embodiment, certain smaller diameters at the narrow end of the cuff taper are associated with increased sealing performance. For example, certain smaller diameters at the narrow end may maintain the sealing band of the cuff around the trachea even though the tube itself may not be centered in the trachea. Due to the curvature typically built into tracheal tubes for ease of insertion and patient comfort, the tube does not necessarily stay centered in the trachea. By having smaller diameters at the narrow end, it is possible to maintain the benefits of the tapered shape even when the tube is not symmetrically located within the trachea. Thus, in certain embodiments it may be desirable to have cuff diameters less than 0.65 inches or less than 0.60 inches at the narrow end of the cuff. The cuff diameters may be even smaller for smaller patients, such as pediatric patients, and in certain embodiments may only be limited by the outer diameter of the tubing that is sufficient to achieve acceptable ventilation of the patient.


In other embodiments, the tapered region of the tapered cuff may be characterized by the slope or angle of the taper, which is the included angle of the tapering cuff wall and the axis of an attached endotracheal tube. For example, the angle of the taper may include a tapering angle of at least 15 degrees, at least 20 degrees, or at least 25 degrees. In a specific embodiment, the angle of the taper may be between 17 and 20 degrees. Providing tapering angles greater than 15 degrees generally indicates a greater variance between the widest point and the narrower point of the taper. Further, the tapered region of the tapered cuff may be characterized in certain embodiments by the rate of tapering from the widest point of the taper to a narrower point. A cuff may exhibit a continuous rate of tapering, or a linear tapering, from a wider diameter to a narrower diameter. Cuffs with linear tapering may be less costly to manufacture. In other embodiments, the taper may have a nonlinear rate of tapering. For example, it may be advantageous to provide stepwise tapering along the cuff, whereby a certain cuff diameter is maintained for 5-10 mm along the length of the taper. The taper may also be characterized by a monotonically decreasing function, such as a hyperbola. Additionally, a taper may be characterized by its length along the axis of an endotracheal tube. For example, a taper may be along at least 30%, at least 40%, at least 50%, at least 75%, or at least 95% of the length of the cuff along a specific axis.


Tapered medical cuffs as provided herein may be used in conjunction with any suitable medical device. In certain embodiments, the tapered cuffs as provided herein may be used in conjunction with a catheter, a stent, a feeding tube, an intravenous tube, an endotracheal tube, a tracheostomy tube, a circuit, an airway accessory, a connector, an adapter, a filter, a humidifier, a nebulizer, or a prosthetic, in various embodiments.


An example of a tapered cuff used in conjunction with a medical device is a cuffed endotracheal tube 10, depicted in FIG. 1. The cuffed endotracheal tube 10 includes an inflatable tapered cuff 12 that may be inflated to form a seal against the trachea wall 28 (see FIG. 2). The tapered cuff is disposed on an endotracheal tube 16 that is suitably sized and shaped to be inserted into a patient and allow the passage of air through the endotracheal tube 16. Typically, the cuff is disposed, adhesively or otherwise, towards the distal end 17 of the endotracheal tube 16. The tapered cuff 12 may be inflated and deflated via a lumen 14 in communication with the tapered cuff 12, typically through a hole or notch in the lumen 14. The tapered cuff 12 may generally have an amorphous, or irregular, shape in the uninflated state and may assume the tapered shape when inflated. The tapered cuff 12 has a proximal opening 20 and a distal opening 22 formed in the cuff walls 24 sized to accommodate the endotracheal tube 16. The proximal opening 20, located closer to the “machine end” of the tube 16, and a distal opening 22, located closer to the “patient end” of the tube 16, are typically used to mount the cuff 12 to the tube 16.


The tapered cuff 12 may be formed from materials having suitable mechanical properties (such as puncture resistance, pin hole resistance, tensile strength), chemical properties (such as forming a suitable bond to the tube 16), and biocompatibility. In one embodiment, the walls of the inflatable cuff 12 are made of a polyurethane having suitable mechanical and chemical properties. An example of a suitable polyurethane is Dow Pellethane® 2363-90A. In another embodiment, the walls of the inflatable cuff 12 are made of a suitable polyvinyl chloride (PVC). Other suitable materials include polypropylene, polyethylene teraphthalate (PETP), low-density polyethylene (LDPE), silicone, neoprene, polyisoprene, or polyurethane (PU).



FIG. 2 shows the exemplary cuffed endotracheal tube 10 inserted into a patient's trachea. The tapered cuff 12 is inflated to form a seal against the tracheal walls 28 and may prevent secretions 30 or other detritus from passing through the trachea into the lungs. The tapered cuff 12 assumes a partially tapered shape when inserted in the patient's trachea, as described in more detail in FIGS. 3-6.


As depicted in FIG. 3, the tapered shape of the cuff 12 may result in different regions of the tapered cuff 12 interacting with the trachea in a variety of manners. One portion of the tapered cuff 12 includes cuff walls with fully inflated diameters larger than the diameter of the tracheal passage 38. As the cuff walls of this region inflate within the trachea, they encounter the tracheal walls 28 and are prevented from assuming their fully inflated diameters, as is normally the case with high volume low pressure cuffs. Thus, the tapered cuff in this region may be partially flattened against the tracheal walls 28 to create a wrinkled region 32 of the cuff (see FIG. 4). A portion of the tapered cuff 12 that includes cuff walls with diameters substantially equal to the diameter of the tracheal passage 38 may form a wrinkle-free band 34 (see FIG. 5) against the tracheal walls 26, as in this region of the tapered cuff 12, the cuff walls assume their fully inflated diameters. The region 36 of the tapered cuff 12 with a diameter smaller than the passage may form a minimal contact or no contact region 36 (see FIG. 6) with the tracheal walls.



FIG. 4 depicts a top view of cross-section through the wrinkled region 32 of an inserted tapered cuff 12. As depicted, the cuff walls 24 may be unable to inflate to their fully inflated diameters in the tracheal passage. In order to fit into the passage, the flexible cuff walls 24 of the tapered cuff 12 fold in on each other and may form multiple wrinkles 40. It should be understood that, depending on how a cuffed endotracheal tube 10 is inserted into the trachea, the tapered cuff 12 may not be completely centered within the tracheal passage.



FIG. 5 depicts a top view of a cross-section through the region of the substantially wrinkle-free band 34 of the tapered cuff 12. The wrinkle-free band 34 is formed in the region of the cuff 12 where the cuff diameter is substantially equal to the patient's trachea. The wrinkle-free band 34 also includes a small part of the cuff 12 with cuff diameters that are only slightly larger than the tracheal diameter, as this part of the cuff does not include cuff diameters that are large enough to support wrinkling or folding. As shown, the cuff walls are generally flush against the tracheal walls 28. As the tracheal walls 28 may be slightly irregular, the wrinkle-free band may vary from patient to patient. Because of the irregular shape of the trachea and the fact that the tube may not be centered radially, the wrinkle-free band 34 may have varying width around its outer diameter as well as have its center vary axially as a function of angular position in the trachea. For example, the plane of the wrinkle-free band 34 may have varying angles, including angles 0-45 degrees off-axis from an axis orthogonal to the patient's trachea. The wrinkle-free band 34 may be characterized by its length along the axis of the tube 16, or along the axis of the patient's trachea. In certain embodiments, the wrinkle-free band 34 provides wrinkle-free contact of least 1 mm along the patient's trachea. In specific embodiments, the wrinkle-free band ranges from 1 mm to 3 mm in size, or from 3 mm to 6 mm in size.



FIG. 6 depicts a top view of a cross-section through the region 36 of the tapered cuff 12 in which the cuff wall diameters are smaller than tracheal diameter. In this minimal contact region 36, the cuff walls are generally not in contact with the patient's tracheal walls, leaving a gap 42 that increases in size as the cuff wall diameter decreases. This arrangement may provide additional advantages related to patient comfort. As a substantial region of the tapered cuff does not contact the trachea walls 28 during use, tracheal tissue irritation may be minimized.


It is also envisioned that a tapered cuff 12 as provided herein may taper away from the distal end of the conduit 16, as shown in FIG. 7. Such an arrangement may provide similar advantages to the taper cuff 12 that tapers towards the distal end of the conduit 16 as provided herein. In other embodiments the inflatable cuff 12 may assume a variety of tapered shapes when inflated. For example, referring now to FIGS. 8 and 9, various exemplary cuff shapes are depicted. FIG. 8 depicts an exemplary cuff 43 having a generally hourglass shape, i.e., two tapered sections 41A and 41B generally connected at their apexes. Similarly, FIG. 9 depicts an exemplary cuff 45 with tapered sections 46A and 46B that is wider at the midsection 44 of the tapered sections 46 than at the proximal end 48 or the distal end 47, i.e., two cones generally connected at their bases. It is envisioned that cuff 43 and cuff 45 may provide the advantage of providing dual wrinkle-free bands along the tracheal walls when inserted into a patient's trachea. The dual bands may provide improved sealing by providing greater total wrinkle-free contact are with the tracheal walls. In certain embodiments, additional cuff shapes that may form multiple wrinkle-free bands are also contemplated. As will be appreciated by those of ordinary skill in the art, other cuff shapes are within the scope of the present disclosure.


The tapered cuffs 12 as provided herein may include cuff walls 24 with constant or varying wall thicknesses along the length of the taper. Cuff wall thickness may vary from the widest part of the taper to the narrowest part of the taper. In certain embodiments, it is advantageous to specify cuff wall thickness variation because certain cuff wall thicknesses in the wrinkle-free band 34 may help to terminate the folds that are present in the wrinkled region 32 of the tapered cuff 12 (as in FIG. 3-FIG. 6). Thicker cuff walls tend to be less flexible than thinner cuff walls, and thus less likely to form wrinkles. If the walls of the wrinkle-free band 34 are thicker than the walls of the wrinkled region 32, the wall thickness may aid in the termination of the wrinkles. Certain wall thicknesses may be associated with wrinkles that are more easily terminated by the “band” that forms at the point where the cuff diameter matches the trachea. In certain embodiments, it is contemplated that at least a portion of the cuff walls in the tapered region of the cuff are less than 60 microns in thickness. In another embodiment, the cuff walls are between 10 microns and 3 millimeters in thickness. In certain embodiments, the cuff walls are between 0.5 mils (where mils are thousandths of an inch) and 3 mils. In specific embodiments, the cuff walls vary along the length of the taper from between 2 microns to 140 microns in thickness, from between 20 microns to 60 microns in thickness, and from between 30 microns to 50 microns in thickness. In certain embodiments, it may be advantageous to provide a cuff 12 with a constant thickness,


This thickness specification may be accomplished in a number of ways. For example, in one embodiment, the tapered cuffs may be manufactured by a blow molding process or extrusion blow molding process. For example, the cuffs may also be made by using preextruded tubing and applying heat and pressure appropriately within a molding cavity to achieve the desired shape (blow molding). These cuffs can also be formed by extrusion blowmolding, wherein an extruder fed polymer pellets melts the polymer and feeds the molten polymer through a die to form a tube shape. This still molten polymer is then captured in a mold and air pressure is applied to expand the tube out to the walls of the mold, thus achieving the desired shape. In the extrusion blow molding process, a core or mandrel of the extruder has apertures to admit a gas such as pressurized air or an inert gas like nitrogen, into the medical device in the neighborhood of the cuff. After a length of medical device has been extruded, a mold clamps the medical device around the mandrel. As gas is admitted to the cuff area through the mandrel, the cuff expands against the mold. In the alternative, the cuff wall may be expanded in a second discrete expansion process following an extrusion or molding process, such as with a shuttle blow molding process. After initial extrusion, the extruded cuff will have a generally tubular shape with a substantially uniform wall thickness. This tubular shape may then be blown into the tapered shape. This process results in the area of the cuff with larger diameters having thinner walls because the same amount of material is stretched over a larger area. In an alternate embodiment, the wall thickness, constant or variable, along the length of the taper may be specified in the blow molding process by using a programmable parasin on the extruder. A programmable parasin allows the wall thickness being extruded to be controlled as a function of length. Therefore, the extruded section may have walls of varying thickness. This extruded section may then be blowmolded as described above. Other cuff shapes and designs are discussed in the U.S. patent application Ser. No. 11/473,362, titled “ENDOTRACHEAL CUFF AND TECHNIQUE FOR USING THE SAME” to Donald S. Nelson and Dhairya Mehta filed on Jun. 22, 2006, the U.S. patent application Ser. No. 11/473,915, titled “ENDOTRACHEAL CUFF AND TECHNIQUE FOR USING THE SAME” to Seamus Maguire, Sean Morris, Paul O'Neill, and Patrick Joseph Tiernan filed on Jun. 22, 2006, and the U.S. patent application Ser. No. 11/473,285, titled “THIN CUFF FOR USE WITH MEDICAL TUBING AND APPARATUS FOR MAKING THE SAME” to Joel Colburn and Roger Caluya filed on Jun. 22, 2006, which are hereby incorporated by reference in their entirety.


One example of such a suitable blow molding process 50 is depicted in the flowchart of FIG. 10. In this example, a tube, such as an extruded polyurethane tube, is loaded (block 52) into a blowing machine or mold assembly with a tapered shape, such as a machine used to blow angioplasty balloons. As described above, the extruded tube may have walls of varying thickness. Balloon blowing machines typically allow process parameters such as extrusion stretch, blow pressure, and temperature to be controlled. Once loaded, the mold assembly is closed, and the tube is clamped at each end (block 54). The tube is stretched and air is blown into the tube via an air conduit, such as an air hose or nozzle, connected to a source of pressurized air, such as an air pump or pre-pressurized source, to achieve a desired positive pressure within the tube (block 56). Heat is applied to the tube (block 58), such as via heating elements integral to the mold assembly. As the heat is applied, the stretch of the tube is relaxed and the air pressure within the tube is increased (block 60). Once the desired temperature is reached it is maintained for an interval of time (block 62). Afterward, the temperature of the mold assembly is allowed to drop or is actively cooled (block 64). A vacuum is applied within the tube, which now includes the blown cuff, to release the tube and cuff from the mold assembly and the tube and cuff are removed from the mold assembly (block 66).


For example, in one particular implementation, a commercially available extrusion of Dow Pellethane® 2363-90A having an inner diameter of 0.239±0.005 inches (6.0706±0.127 mm) and a wall thickness of 0.008 inches (0.2032 mm) may be blown to form a cuff 12 suitable for use with a 7.5 mm internal diameter (ID) endotracheal tube. The extruded tube may be stretched 50 to 100 mm on each end and a pressure of 1.0 to 2.0 bar is applied within the extruded tube. The extruded tube is heated for 50 to 100 seconds. As the temperature ramps up, the stretched ends of the extruded tube are relaxed to 20 to 70 mm and the air pressure within the extruded tube is increased to 1.5 to 2.1 bar. The temperature is allowed to increase to 120 to 150° C., where it is maintained for 10 to 30 seconds. The mold assembly is then cooled to 40 to 55° C., a vacuum is applied to the molded extrusion and cuff, and the extrusion and cuff are removed from the mold assembly. In another embodiment, the cuff wall thickness may be controlled by a dip coating process (not shown). For example, by controlling the withdrawal rate of a cuff mandrel from a dip coating solution, the wall thickness can be controlled. Using this control or multiple dips, it is possible to obtain even step function changes in wall thickness.


In certain embodiments, it may be desirable for the tapered cuff to include an antimicrobial surface to prevent the adhesion and propagation of biofilms. As shown in FIG. 11, a wall 24 of a cuff 12 may be a hydrophobic polymer with an outer antimicrobial layer 78 that includes a hydrophilic polymer and an antimicrobial compound disposed on an outer surface 80 of the cuff wall 24. The antimicrobial layer may include an antimicrobial metal, such as copper, silver, or gold. In several exemplary embodiments, the metal may be elemental silver, powdered silver, silver ions (Ag+), or a silver bearing material like silver oxide (AgO). The hydrophilic layer may thus be an antimicrobial (AM) layer. In this way the colonization-inhibiting properties of the hydrophilic surface can be reinforced by antimicrobial properties.


It may be desirable for the metal to be released over time, while the medical device is in use. In one embodiment, therefore, a silver-bearing time-release material may be a phosphorus-based glass material that dissolves in water at a rate that may be a function of its particular formulation. The glass may also contain trace amounts of other elements, such as calcium oxide (CaO). The rate at which silver is released may further be a function of the rate at which the phosphorus-based glass material dissolves in water. The silver, or the phosphorus-based glass material, or both, may be powdered. The release of silver over time, which is defined as the elution rate and is measured in micrograms/cm2/day, may thus be tailored to the specific needs of the application by specifying the formulation of the phosphorus-based glass material, such as the material described in U.S. Pat. No. 6,143,318. In one embodiment, the silver bearing material may be made up of about 5-10% by weight, e.g. about 7.5% phosphorus-based glass by weight. Such a material is available from Giltech Limited, 12 North Harbour Industrial Estate, Ayr, Scotland, Great Britain KA8 8BN. In one embodiment, the elution rate should be up to about 0.01 micrograms/cm2/day. In another embodiment, the elution rate may be between about 0.01 and 1.0 micrograms/cm2/day. In another embodiment, the elution rate may be about 0.4 micrograms/cm2/day.


In other embodiments, bioactive pharmaceutical agents such as a bronchodilator, an anti-inflammatory agent, or a local anesthetic, may be substantially dispersed in a phosphorus-based glass material within a hydrophilic layer. Such bioactive pharmaceutical agents may be delivered to and absorbed by adjacent tissues in substantially the same manner as silver. Regulation and control of dosage, elution rate, and thickness, in substantially the same manner as silver, may also provide a beneficial pharmacologic or therapeutic action.


A hydrophilic coating may be applied to the surface of a medical device by, e.g., extruding, molding, dipping, spraying, washing, or painting the hydrophilic coating on the surface. In one embodiment, a medical device may be formed by extruding a wall of hydrophobic material along with one or more layers of an antimicrobial material. In another embodiment, a medical device may be formed by molding a wall of hydrophobic material along with one or more layers of an antimicrobial material. The antimicrobial layer may be formed on an inner or an outer surface of the medical device wall. The antimicrobial layer may be comprised of, e.g., polyurethane, such as a medical grade hydrophilic thermoplastic polyurethane into which has been substantially dispersed a silver-bearing phosphorus-based glass material. In one embodiment, the antimicrobial layer may be within a range of about 0.002 mm-2.5 mm in thickness, or about 0.13 mm in thickness. In another embodiment, the antimicrobial layer may be within a range of about 0.002 mm-2.5 mm in thickness. In another embodiment, the antimicrobial layer may be up to about 6.35 mm in thickness. In another embodiment, the hydrophobic polymer, hydrophilic polymer and the antimicrobial compound may be compounded together and extruded to form a cuff wall 24.


The tracheal cuffs of the present techniques may be incorporated into systems that facilitate positive pressure ventilation of a patient, such as a ventilator. Such systems may typically include connective tubing, a gas source, a monitor, and/or a controller. The controller may be a digital controller, a computer, an electromechanical programmable controller, or any other control system.


Typically, endotracheal cuffs are inflated within a patient's trachea such that the intra cuff pressure is approximately 20-25 cm H2O. Endotracheal cuffs utilizing inflation pressures significantly greater 25 cm H2O may be referred to as high-pressure cuffs, while cuffs that are able to effectively seal the trachea at pressures less than 30 cm H2O may be considered low-pressure cuffs. In certain embodiments, intra cuff inflation pressures of 10-30 cm H2O may be used with the tapered cuffs of the present techniques.


While the invention may be susceptible to various modifications and alternative forms, specific embodiments have been shown by way of example in the drawings and have been described in detail herein. However, it should be understood that the invention is not intended to be limited to the particular forms disclosed. Rather, the invention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the invention as defined by the following appended claims.

Claims
  • 1. An inflatable balloon cuff comprising: a tapered section of the inflatable balloon cuff, wherein at least a portion of the tapered section is adapted to form a seal against a tracheal wall of a patient, wherein the inflatable balloon cuff is characterized in that the tapered section comprises: a sealing portion, wherein the sealing portion is adapted to form a wrinkle-free band against a patient's tracheal wall when inflated, such that a portion of the tapered region is configured to form a seal against the patient's trachea and-wherein the seal reduces microaspiration of fluids by an average of 90% relative to an inflatable balloon cuff having a barrel shape when coupled to a tracheal tube having a 7.5 mm inner diameter; and a wrinkled portion, wherein a largest diameter of the wrinkled portion is larger than a tracheal diameter such that the wrinkled portion forms a wrinkled band against a patient's tracheal wall when inflated and wherein the wrinkled band is longer than the wrinkle-free band.
  • 2. The inflatable balloon cuff of claim 1, wherein the tapered section comprises a substantially constant taper rate along the length of the tapered section.
  • 3. The inflatable balloon cuff of claim 1, wherein the balloon cuff is configured to be inflated to intra cuff inflation pressures of 10-30 cm H2O.
  • 4. The inflatable balloon cuff of claim 1, wherein the wrinkle-free sealing band is between 1-3 millimeters in length.
  • 5. The inflatable balloon cuff of claim 1, wherein the wrinkle-free sealing band is between 3-6 millimeters in length.
  • 6. The inflatable balloon cuff of claim 1, wherein the balloon cuff comprises one or more of polyethylene teraphthalate (PETP), low-density polyethylene (LDPE), polyvinyl chloride (PVC), silicone, neoprene, polyisoprene, polypropylene, or polyurethane (PU).
  • 7. The inflatable balloon cuff of claim 1, wherein narrowest portion of the tapered section has a balloon wall diameter that is less than 0.60 inches when the balloon cuff is fully inflated.
  • 8. The inflatable balloon cuff of claim 1, wherein the tapered section comprises balloon wall diameters between 1.75 inches and 0.15 inches when the balloon cuff is fully inflated.
  • 9. The inflatable balloon cuff of claim 1, wherein the tapered section comprises balloon wall thicknesses between 0.5 mils and 3 mils.
  • 10. A balloon cuff comprising: a tapered section, wherein at least a portion of the tapered section is adapted to form a seal against the patient's trachea that reduces microaspiration of fluids by an average of 90% relative to a barrel-shaped cuff when the balloon cuff is inflated to an intracuff pressure of 10-30 cm H2O and wherein the barrel-shaped cuff is coupled to a tracheal tube of a same inner diameter in a same size trachea for the comparison;and wherein at least a portion of the tapered section is adapted to form a wrinkled band against the tracheal wall, wherein the wrinkled band is longer than the wrinkle-free sealing band when the balloon cuff is inflated within the trachea.
  • 11. The balloon cuff of claim 10, wherein the wrinkled portion is disposed on the cuff proximally of the wrinkle-free sealing band.
  • 12. The balloon cuff of claim 10, wherein the wrinkle-free sealing band is formed when the inflatable balloon cuff is inflated to an intracuff pressure of 20-25 cm H2O.
  • 13. The balloon cuff of claim 10, wherein the wrinkle-free sealing band is between 1-3 millimeters in length.
  • 14. The balloon cuff of claim 10, wherein the balloon cuff is coupled to a tracheal tube.
  • 15. A tracheal tube comprising: a conduit; anda balloon cuff coupled to the conduit, wherein the balloon cuff comprises:a tapered section comprising: a sealing portion, wherein the sealing portion is adapted to form a wrinkle-free band against a patient's tracheal wall when inflated, wherein the wrinkle-free sealing band is configured to prevent leakage of fluid past the wrinkle-free sealing band when inflated by an average of 90% relative to a barrel-shaped cuff having a largest diameter that is greater than a tracheal diameter along a majority of a length of the barrel-shaped cuff; anda wrinkled portion, wherein a largest diameter of the wrinkled portion is larger than a tracheal diameter such that the wrinkled portion forms a wrinkled band against a patient's tracheal wall when inflated and wherein the wrinkled band is longer than the wrinkle-free band.
  • 16. The tracheal tube of claim 15, wherein the wrinkled portion is disposed on the cuff proximally of the wrinkle-free sealing band.
  • 17. The tracheal tube of claim 15, wherein the wrinkle-free sealing band is formed when the inflatable balloon cuff is inflated to an intracuff pressure of 20-25 cm H2O.
  • 18. The tracheal tube of claim 15, wherein the tracheal tube is an endotracheal tube.
  • 19. The tracheal tube of claim 15, wherein the tracheal tube is a tracheostomy tube.
  • 20. The tracheal tube of claim 15, wherein the balloon cuff comprises one or more of polyethylene teraphthalate (PETP), low-density polyethylene (LDPE), polyvinyl chloride (PVC), silicone, neoprene, polyisoprene, polypropylene, or polyurethane (PU).
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of application Ser. No. 14/703,525, filed May 4, 2015, entitled “Endotracheal Cuff and Technique for Using the Same”, in the name of Donald S. Nelson et al., which is a continuation of application Ser. No. 14/137,241, filed on Dec. 20, 2013, entitled “Endotracheal Cuff and Technique for Using the Same” in the name of Donald S. Nelson et al., which is a continuation of application Ser. No. 13/612,397, filed Sep. 12, 2012, entitled “Endotracheal Cuff and Technique for Using the Same” in the name of Donald S. Nelson et al., now U.S. Pat. No. 8,636,010 which issued on Jan. 28, 2014, which is a continuation of U.S. application Ser. No. 11/472,733, filed on Jun. 22, 2006, now U.S. Pat. No. 8,434,487, which issued on May 7, 2013, the disclosures of which are incorporated by reference herein in their entireties.

US Referenced Citations (300)
Number Name Date Kind
2099127 Leech Nov 1937 A
2133345 Davis Oct 1938 A
2765559 Morris Oct 1956 A
2927584 Wallace Mar 1960 A
3610247 Jackson Oct 1971 A
3709227 Hayward Jan 1973 A
3734100 Walker et al. May 1973 A
3769983 Merav Nov 1973 A
3810474 Cross May 1974 A
3822238 Blair et al. Jul 1974 A
3913565 Kawahara Oct 1975 A
3971385 Corbett Jul 1976 A
3975350 Hudgin et al. Aug 1976 A
3995643 Merav Dec 1976 A
4022217 Rowean May 1977 A
4130617 Wallace Dec 1978 A
4230108 Young Oct 1980 A
4231365 Scarberry Nov 1980 A
4235239 Elam Nov 1980 A
4340046 Cox Jul 1982 A
4511354 Sterling Apr 1985 A
4569344 Palmer Feb 1986 A
4638539 Palmer Jan 1987 A
4649913 Watson Mar 1987 A
4696296 Palmer Sep 1987 A
4700700 Eliachar Oct 1987 A
4791920 Fauza Dec 1988 A
4825859 Lambert May 1989 A
4825861 Koss May 1989 A
4834726 Lambert May 1989 A
4836199 Palmer Jun 1989 A
4838255 Lambert Jun 1989 A
4850348 Pell et al. Jul 1989 A
4867153 Lorenzen et al. Sep 1989 A
4872579 Palmer Oct 1989 A
4886059 Weber Dec 1989 A
4927412 Menasche May 1990 A
4938741 Lambert Jul 1990 A
4963313 Noddin et al. Oct 1990 A
4967743 Lambert Nov 1990 A
4979505 Cox Dec 1990 A
5020534 Pell et al. Jun 1991 A
5021045 Buckberg et al. Jun 1991 A
5025806 Palmer et al. Jun 1991 A
5029580 Radford et al. Jul 1991 A
5033466 Weymuller, Jr. Jul 1991 A
5060646 Page Oct 1991 A
5065754 Jensen Nov 1991 A
5074840 Yoon Dec 1991 A
5076268 Weber Dec 1991 A
5098379 Conway et al. Mar 1992 A
5103816 Krischbaum et al. Apr 1992 A
5107829 Lambert Apr 1992 A
5120322 Davis et al. Jun 1992 A
5122122 Allgood Jun 1992 A
5133345 Lambert Jul 1992 A
5135516 Sahatjian et al. Aug 1992 A
5137671 Conway et al. Aug 1992 A
5158569 Strickland et al. Oct 1992 A
5165420 Strickland Nov 1992 A
5176638 Don Michael Jan 1993 A
5190810 Kirschbaum et al. Mar 1993 A
5199427 Strickland Apr 1993 A
5201310 Turnbull et al. Apr 1993 A
5207643 Davis May 1993 A
5215522 Page et al. Jun 1993 A
5218957 Strickland Jun 1993 A
5230332 Strickland Jul 1993 A
5233979 Strickland Aug 1993 A
5246012 Strickland Sep 1993 A
5250070 Parodi Oct 1993 A
5251619 Lee Oct 1993 A
5261896 Conway et al. Nov 1993 A
5263478 Davis Nov 1993 A
5269770 Conway et al. Dec 1993 A
5277177 Page et al. Jan 1994 A
5285777 Beckwith Feb 1994 A
5290585 Elton Mar 1994 A
5304121 Sahatjian Apr 1994 A
5305740 Kolobow Apr 1994 A
5331027 Whitbourne Jul 1994 A
5360402 Conway et al. Nov 1994 A
5370656 Shevel Dec 1994 A
5370899 Conway et al. Dec 1994 A
5374261 Yoon Dec 1994 A
5392787 Yoon Feb 1995 A
5397302 Weaver et al. Mar 1995 A
5407423 Yoon Apr 1995 A
5417671 Jackson May 1995 A
5423745 Todd et al. Jun 1995 A
5423754 Cornelius et al. Jun 1995 A
5439457 Yoon Aug 1995 A
5443063 Greenberg Aug 1995 A
5447152 Kohsai et al. Sep 1995 A
5447505 Valentine et al. Sep 1995 A
5451204 Yoon Sep 1995 A
5466231 Cercone et al. Nov 1995 A
5469864 Rosenblatt Nov 1995 A
5482740 Conway et al. Jan 1996 A
5484426 Yoon Jan 1996 A
5487730 Maracadis et al. Jan 1996 A
5494029 Lane et al. Feb 1996 A
5501669 Conway et al. Mar 1996 A
5507284 Daneshvar Apr 1996 A
5509899 Fan et al. Apr 1996 A
5524642 Rosenblatt Jun 1996 A
5545132 Fagan et al. Aug 1996 A
5556391 Cercone et al. Sep 1996 A
5567203 Euteneuer et al. Oct 1996 A
5593718 Conway et al. Jan 1997 A
5599292 Yoon Feb 1997 A
5599299 Weaver et al. Feb 1997 A
5599321 Conway et al. Feb 1997 A
5611336 Page et al. Mar 1997 A
5613950 Yoon Mar 1997 A
5620457 Pinchasik et al. Apr 1997 A
5649902 Yoon Jul 1997 A
5653229 Greenberg Aug 1997 A
5670111 Conway et al. Sep 1997 A
5674192 Sahatjian et al. Oct 1997 A
5693014 Abele et al. Dec 1997 A
5694902 Miwa et al. Dec 1997 A
5694922 Palmer Dec 1997 A
5697235 Pell Dec 1997 A
5697365 Pell Dec 1997 A
5700239 Yoon Dec 1997 A
5715815 Lorenzen et al. Feb 1998 A
5720726 Marcadis et al. Feb 1998 A
5722931 Heaven Mar 1998 A
5730123 Lorenzen Mar 1998 A
5733252 Yoon Mar 1998 A
5735271 Lorenzen et al. Apr 1998 A
5746762 Bass May 1998 A
5765559 Kim Jun 1998 A
5769882 Fogarty et al. Jun 1998 A
5810786 Jackson et al. Sep 1998 A
5819733 Bertram Oct 1998 A
5827215 Yoon Oct 1998 A
5843017 Yoon Dec 1998 A
5843028 Weaver et al. Dec 1998 A
5843060 Cercone Dec 1998 A
5843089 Sahatjian et al. Dec 1998 A
5868719 Tsukernik Feb 1999 A
5868775 Bircoll Feb 1999 A
5908406 Ostapchenko Jun 1999 A
5951597 Westlund et al. Sep 1999 A
5954706 Sahatjian Sep 1999 A
5954740 Ravenscroft et al. Sep 1999 A
5970111 Samarasekera et al. Oct 1999 A
5971954 Conway et al. Oct 1999 A
5974192 Kundu Oct 1999 A
5976072 Greenberg Nov 1999 A
5976199 Wu et al. Nov 1999 A
5997503 Willis et al. Dec 1999 A
5997546 Foster et al. Dec 1999 A
6010480 Abele et al. Jan 2000 A
6012451 Palmer Jan 2000 A
6048332 Duffy et al. Apr 2000 A
6110192 Ravenscroft et al. Aug 2000 A
6123698 Spears et al. Sep 2000 A
6129547 Cise Oct 2000 A
6143318 Gilchrist et al. Nov 2000 A
6152136 Pagan Nov 2000 A
6169123 Cercone Jan 2001 B1
6210364 Anderson et al. Apr 2001 B1
6214895 Cercone Apr 2001 B1
6227200 Crump et al. May 2001 B1
6240321 Janke et al. May 2001 B1
6248088 Yoon Jun 2001 B1
6264631 Willis et al. Jul 2001 B1
6264633 Knorig Jul 2001 B1
6277089 Yoon Aug 2001 B1
6312421 Boock Nov 2001 B1
6322586 Monroe et al. Nov 2001 B1
6364856 Ding et al. Apr 2002 B1
6378521 Van Den Berg Apr 2002 B1
6394093 Lethi May 2002 B1
6395012 Yoon et al. May 2002 B1
6398266 Crump Jun 2002 B1
6409716 Sahatjian et al. Jun 2002 B1
6481436 Neame Nov 2002 B1
6494203 Palmer Dec 2002 B1
6524274 Rosenthal et al. Feb 2003 B1
6526977 Göbel Mar 2003 B1
6528150 Nazarova et al. Mar 2003 B2
6543451 Crump et al. Apr 2003 B1
6551272 Göbel Apr 2003 B2
6572813 Zhang et al. Jun 2003 B1
6584970 Crump et al. Jul 2003 B1
6588425 Rouns et al. Jul 2003 B2
6588427 Carlsen et al. Jul 2003 B1
6602218 Yoon Aug 2003 B2
6602219 Madsen et al. Aug 2003 B2
6607545 Kammerer et al. Aug 2003 B2
6609520 Carlsen et al. Aug 2003 B1
6612304 Cise et al. Sep 2003 B1
6612305 Fauza Sep 2003 B2
6613025 Palasis Sep 2003 B1
6615835 Cise et al. Sep 2003 B1
6619530 Ushiki et al. Sep 2003 B2
6620128 Simhambhatla Sep 2003 B1
6623450 Dutta Sep 2003 B1
6629530 Cise Oct 2003 B2
6632091 Cise et al. Oct 2003 B1
6638245 Miller et al. Oct 2003 B2
6651664 Lomholt Nov 2003 B1
6688306 Cise et al. Feb 2004 B1
6698424 Madsen et al. Mar 2004 B2
6705320 Anderson Mar 2004 B1
6712832 Shah Mar 2004 B2
6722368 Shaikh Apr 2004 B1
6726696 Houser et al. Apr 2004 B1
6745773 Gobel Jun 2004 B1
6746424 Stamberg Jun 2004 B2
6767340 Willis et al. Jul 2004 B2
6767640 Moffatt Jul 2004 B2
6769430 Carlsen et al. Aug 2004 B1
6770066 Weaver et al. Aug 2004 B1
6772368 Dhong et al. Aug 2004 B2
6786876 Cox Sep 2004 B2
6790221 Monroe et al. Sep 2004 B2
6796309 Nash et al. Sep 2004 B2
6802317 Göbel Oct 2004 B2
6805125 Crump et al. Oct 2004 B1
6808521 McMichael Oct 2004 B1
6814730 Li Nov 2004 B2
6890339 Sahatjian et al. May 2005 B2
6908449 Willis et al. Jun 2005 B2
6916307 Willis et al. Jul 2005 B2
6923786 Rouns et al. Aug 2005 B2
6997909 Goldberg Feb 2006 B2
7040321 Gobel May 2006 B2
7040322 Fortuna May 2006 B2
7066905 Squire et al. Jun 2006 B2
7147252 Teuscher et al. Dec 2006 B2
7258120 Melker Aug 2007 B2
8232337 Martens et al. Jul 2012 B2
8434487 Nelson et al. May 2013 B2
8636010 Nelson et al. Jan 2014 B2
9032957 Nelson et al. May 2015 B2
20010016724 Davis et al. Aug 2001 A1
20020032407 Willis et al. Mar 2002 A1
20020077603 Willis et al. Jun 2002 A1
20020077604 Willis et al. Jun 2002 A1
20020078960 Cise Jun 2002 A1
20020078963 Rouns et al. Jun 2002 A1
20020082552 Ding et al. Jun 2002 A1
20020082553 Duchamp Jun 2002 A1
20020091375 Sahatjian et al. Jul 2002 A1
20020193753 Rouns et al. Dec 2002 A1
20020195110 Watton Dec 2002 A1
20030000526 Gobel Jan 2003 A1
20030069620 Li Apr 2003 A1
20030111077 Hooser et al. Jun 2003 A1
20030116162 Madsen et al. Jun 2003 A1
20030116963 Teuscher et al. Jun 2003 A1
20030225369 McMichael et al. Dec 2003 A1
20030225392 McMichael et al. Dec 2003 A1
20030225393 McMichael et al. Dec 2003 A1
20040024363 Goldberg Feb 2004 A1
20040079376 Melker Apr 2004 A1
20040092870 Squire et al. May 2004 A1
20040106899 McMichael et al. Jun 2004 A1
20040106900 Triebes et al. Jun 2004 A1
20040106901 Letson et al. Jun 2004 A1
20040116898 Hawk Jun 2004 A1
20040152945 Kantrowitz et al. Aug 2004 A1
20040154623 Schaeffer et al. Aug 2004 A1
20040193100 Van Hooser et al. Sep 2004 A1
20040193101 Van Hooser et al. Sep 2004 A1
20040215142 Matheis et al. Oct 2004 A1
20040220534 Martens et al. Nov 2004 A1
20040221853 Miller Nov 2004 A1
20040255951 Grey Dec 2004 A1
20040255952 Carlsen et al. Dec 2004 A1
20050004560 Cox Jan 2005 A1
20050033267 Decaria Feb 2005 A1
20050033268 Decaria Feb 2005 A1
20050033269 Decaria Feb 2005 A1
20050038381 McMichael Feb 2005 A1
20050065468 Goebel Mar 2005 A1
20050124932 Foster et al. Jun 2005 A1
20050124935 McMichael Jun 2005 A1
20050137619 Schewe et al. Jun 2005 A1
20050166924 Thomas et al. Aug 2005 A1
20070038109 Nierich Feb 2007 A1
20070295336 Nelson et al. Dec 2007 A1
20070295337 Nelson et al. Dec 2007 A1
20070296125 Colburn et al. Dec 2007 A1
20080000482 Maguire et al. Jan 2008 A1
20080078400 Martens Apr 2008 A1
20080078403 Clayton Apr 2008 A1
20080078404 Martens Apr 2008 A1
20080142016 Colburn et al. Jun 2008 A1
20080210243 Clayton et al. Sep 2008 A1
20080215034 Clayton Sep 2008 A1
20080236593 Nelson et al. Oct 2008 A1
20120125346 Clayton May 2012 A1
20130000650 Nelson et al. Jan 2013 A1
20130008451 Nelson et al. Jan 2013 A1
Foreign Referenced Citations (42)
Number Date Country
2353007 Jun 2000 CA
20072654938 Jun 2007 CA
2654938 Dec 2007 CA
4334037 Apr 1995 DE
19500550 Jul 1996 DE
19855521 Jun 2000 DE
0884061 Dec 1998 EP
0922465 Jun 1999 EP
1267981 Apr 2000 EP
1005877 Jun 2000 EP
1005877 Jun 2000 EP
1135184 Jun 2000 EP
07795681.1 Jun 2007 EP
2029210 Mar 2009 EP
09726613.4 Mar 2009 EP
2276534 Jan 2011 EP
2689794 Jan 2014 EP
1402255 Aug 1975 GB
2168256 Jun 1986 GB
2168256 Jun 1986 GB
2326099 Dec 1998 GB
2344528 Jun 2000 GB
2000167060 Jun 2000 JP
2006522623 Oct 2006 JP
2009516497 Jun 2007 JP
2009540922 Nov 2009 JP
WO9522367 Aug 1995 WO
WO0027461 May 2000 WO
WO0032262 Jun 2000 WO
WO0197890 Dec 2001 WO
WO03045487 Jun 2003 WO
WO2004067262 Aug 2004 WO
WO2004089453 Oct 2004 WO
WO2004101046 Nov 2004 WO
WO2006023486 Mar 2006 WO
PCTUS2007013085 Jun 2007 WO
PCTUS2007013086 Jun 2007 WO
WO2007149202 Dec 2007 WO
WO2007149203 Dec 2007 WO
WO2007149301 Dec 2007 WO
PCTUS2009036654 Mar 2009 WO
WO2009123835 Oct 2009 WO
Non-Patent Literature Citations (87)
Entry
U.S. Appl. No. 11/472,733; US20070295336, filed Jun. 22, 2006; Dec. 27, 2007, Nelson, Donald S.
U.S. Appl. No. 11/473,362; US20070295337, filed Jun. 22, 2006; Dec. 27, 2007, Nelson, Donald S.
U.S. Appl. No. 12/059,556; US20080236593, filed Mar. 31, 2008; Oct. 2, 2008, Nelson, Donald S.
U.S. Appl. No. 13/612,381; US20130000650, filed Sep. 12, 2012; Jan. 3, 2013, Nelson, Donald S.
U.S. Appl. No. 14/137,241; U.S. Pat. No. 9,032,957, filed May 19, 2015, Nelson, Donald S.
File History of U.S. Appl. No. 11/472,733, filed Jun. 22, 2006.
File History of U.S. Appl. No. 11/473,362, filed Jun. 22, 2006.
File History of U.S. Appl. No. 12/059,556, filed Mar. 31, 2008.
File History of U.S. Appl. No. 13/612,381, filed Sep. 12, 2012.
File History of U.S. Appl. No. 13/612,397, filed Sep. 12, 2012.
File History of Japanese Patent Application No. JP2009516497, filed Jun. 1, 2007.
File History of European Patent Application No. EP07795681.1, filed Jun. 1, 2007.
File History of European Patent Application No. EP09726613.4, filed Mar. 10, 2009.
File History of Canadian Patent Application No. CA20072654938, filed Dec. 9, 2008.
Chien et al., “Impact of Cuff Shape on Outcomes of Patients Intubated with Endotracheal Tubes with Subglottic Secretion Drainage,” (Covidien and Brigham and Women's Hospital, Boston, MA) Poster # 44442; 13-AW-0017 PST TaperGuard Barrel Shape Outcomes Poster High Res.
Kimberly-Clark Microcuff Adult Endotracheal Tubes—Product Technical Update: Cuff Condensation (undated).
Lichtenthal et al., Respiratory—Airway Management, A89—Do Endotracheal Tubes Prevent Microaspiration? (undated).
Lichtenthal, P., “Do endotracheal tubes prevent microaspiration?”, BJA pp. 821-822 DOI:10.1093/bja/aer312.
MALLINCKRODT™ TaperGuard™ Endotracheal Tubes Manage secretions more effectively in the operating room; Covidien (undated).
Molnlycke Steritex, Facts about the NL-Tube with Cuff-Inflator—the tracheostomy system with controlled cuff pressure (undated).
TaperGuard™ product literature (undated).
King et al., Tracheal tube cuffs and tracheal dilation, CHEST® 67; 458-462 (1975).
Seegobin, et al., Endotracheal cuff pressure and tracheal mucosal blood flow: endoscopic study of effects of four large volume cuffs, British Medical Journal, vol. 288, pp. 965-968; Mar. 31, 1984.
Petring et al., Prevention of Silent Aspiration Due to Leaks around Cuffs of Endotracheal Tubes, Anesth Analg 65:777-80 (1986).
Seegobin, Ronald D. and van Hasselt, Gillian L., Aspiration beyond endotracheal cuffs, CAN Anaesth. Soc. J. 33:3/pp. 273-279 (1986).
Mahul et al., Prevention of nosocomial pneumonia in intubated patients: respective role of mechanical subglottic secretions drainage and stress ulcer prophylaxis, Intensive Care Med 18:20-25 (1992).
Oikkonen et al., Apparatus Leakage of fluid around low-pressure tracheal tube cuffs, Anesthesia (1997) 52:567-569, Blackwell Science Ltd. (1997).
Sartomer Application Bulletin; “Functional Acrylic Monomers as Modifiers for PVC Plastisol Formulations,” pp. 1-6. (1997).
Blunt et al.; “Gel Lubrication of the Tracheal Tube Cuff Reduces Pulmonary Aspiration,” 2001 American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc.; Anesthesiology, V. 95, No. 2, Aug. 2001.
Sittig, Steven E. and Pringnitz, James E., Tracheostomy: Evolution of an Airway, AARC Times, (Feb. 2001) pp. 48-51.
Aye Gönen Karakeç{dot over (i)}l{dot over (i)} et al.; “Comparison of Bacterial and Tissue Cell Initial Adhesion on Hydrophilic/Hydrophobic Biomaterials,” J Biomater. Sci. Polymer Edn, vol. 13, No. 2, pp. 185-196 (2002).
SHERIDAN® Endotracheal Tubes—Hudson RCI—Breathing made easier (2002).
Dullenkopf, et al., “Fluid leakage past tracheal tube cuffs: evaluation on the new Microcuff endotracheal tube,” Intensive Care Medicine, (2003) vol. 29, pp. 1849-1853.
Tecogel brochure page, Noveon Thermedics Polymer Products, Oct. 2003.
Shintani; “Modification of Medical Device Surface to Attain Anti-Infection,” National Institute of Health Sciences; Trends Biomater. Artif. Organs, vol. 18(1), pp. 1-8 (2004).
Kimberly-Clark Microcuff Endotracheal Tube—Revolutionary cuff material designed to reduce micro-aspiration, Ventilator-Associated Pneumonia, Kollef, et al. Respiratory Care, 2005.
Kimberly-Clark Microcuff Pediatric Endotracheal Tube, Finally a cuffed ET tube designed for the pediatric anatomy, Weiss et al. Br J. Anaesthesia 2005.
Fine et al., “New Advances in Pediatric Ventilation: Revolutionizing the Management of Pediatric Intubation with Cuffed Tubes”, Pediatric Microcuff Endotracheal Tube 2006.
Gerber et al., “Cuffed tubes for infants and children in anaesthesia and intensive care: Why we should change to cuffed tubes in paediatric airway management,” Review Article, Journal of Paediatric Respiratory and Critical Care (Dec. 2008).
Kollef, et al., Silver-Coated Endotracheal Tubes and Incidence of Ventilator-Associated Pneumonia, The Nascent Randomized Trial, 2008 American Medical Association, reprinted JAMA, vol. 300, No. 7, pp. 805-813; Aug. 20, 2008.
Mecca et al., Benchtop comparison: Fluid sealing performance of barrel-shaped versus taper-shaped polyvinyl chloride (PVC) high volume, low-pressure endotracheal tube cuffs Oct. 2008.
Poelaert et al., “Polyurethane cuffed endotracheal tubes to prevent early postoperative pneumonia after cardiac surgery: A pilot study,” Cardiopulmonary Support and Physiology, The Journal of Thoracic and Cardiovascular Surgery, Apr. 2008, vol. 135, No. 4, pp. 771-776.
Swiss Medical Weekly, Supplement 166, The European Journal of Medical Sciences, Annual Meeting—Swiss Society of Anaesthesiology and Resuscitation (2008).
2009 Press Release—Kimberly-Clark Health Care Microcuff Pediatric ET tube—Clinical Study Shows Benefit of Cuffed Over Uncuffed Endotracheal Tubes in Pediatric Patients (Roswell, GA—Jan. 7, 2009).
2009 Press Release—Kimberly-Clark Microcuff Adult Endotracheal Tube Shown to Reduce the Incidence of Ventilator-Associated Pneumonia (Roswell, GA—May 19, 2009).
International Search Report PCT/US2009/036654, 6 pages, dated Jun. 15, 2009.
K090352—Covidien Special 510(k) Summary, (Apr. 3, 2009).
Karlnoski et al., “Low-Pressure Microcuff Adult Endotracheal Tube Reduces the Incidence of Ventilator-Associated Pneumonia”, Poster 19; Clinical Abstract, microcuff reduces vap, tampa general study, ASCCA meeting (Oct. 2009).
Marcus, “Study: Overblown Cuffs Common During Surgery—UK Analysis Finds Averages Well Above Recommended Limit”, Anesthesiology News, Issue: Oct. 2009/vol. 35:10; http.//www.anesthesiologynews.com/printview.asp?article_id=. . . .
Miller et al., “A Polyurethane Cuffed Endotracheal Tube (PUC-ETT) Was Associated with Decreased Rates of Ventilator-Associated Pneumonia”, Univ. of Michigan Health System, Div. of Pulmonary and Critical Care Medicine (2009).
Rose et al., “Microaspiration and Endotracheal Tube Cuff Leakage; a Bench Study Comparing Polyurethane and Polyvinyl Chloride Endotracheal Tube Cuff Design”, Texas Health Presbyterian Hospital, Dallas (2009).
Truscott, W., “The Strengths and Weaknesses of Endotracheal Tube Cuffs”, Infection Protection (Aug. 2009).
Weiss et al., “Prospective Randomized Controlled Multi-Centre Trial of Cuffed or Uncuffed Endotracheal Tubes in Small Children,” Paediatrics, British Journal of Anaesthesia 103(6): 867-73 (Dec. 2009).
Batchelder et al., Leak Rates of Three Endotracheal Tube Cuff Designs over a Range of Artificial Trachea Sizes and Cuff Pressures (2010).
Batchelder, P.B., “S-233-Seal Effectiveness of Seven Endotracheal Tube Cuff Designs: A Study Using an in-vitro Model Trachea,” http://www.abstractsonline.com/Plan/AbstractPrintView.aspx?mID=2481&sKey=78a49ea . . . Apr. 19, 2010.
Batchelder, P.B., S-233—Seal Effectiveness of Seven Endotracheal Tube Cuff Designs: A Study Using an in Vitro Model Trachea, http://www.abstractsonline.com/Plan/AbstractPrintView.aspx?mID=2481&sKey=78a49ea . . . Mar. 17, 2010.
Dave et al., Respiration and the Airway—Effect of tracheal tube cuff shape on fluid leakage across the cuff: an in vitro study, British Journal of Anaesthesia 105 (4) 538-43 (2010).
Kimberly-Clark KimVent, VAP Solutions—Helping you protect your patients fromVAP (2010).
Lichtenthal, P., “Do endotracheal tubes prevent microaspiration?”, Critical Care 2010, 14 Suppl 1:p. 229(DOI:10.1186/cc8461) S79.
Mulier et al., “Evaluation of Silent Aspiration in Morbid Obese Patients during Laparoscopic Gastric Bypass Surgery,” Proceedings of the 2010 Annual Meeting of the American Society Anesthesiologists. http://www.asaabstracts.com/strands/asaabstracts/printAbstract.htm.jessesionid=C2E9590E . . . Jul. 23, 2010.
Van Den Brande et al., “Tracheal cuff leak in morbid obese patients intubated with a taperguard or a hi-lo cuffed endotracheal tube evaluated by bronchoscopy,” Eur J Anaesthesiol 2010; 27 (Suppl 47):19AP2-9.
Batchelder et al., “Leak Rates of 3 ET Tube Cuff Designs over a Range of Artificial Trachea Sizes and Cuff Pressures,” Abstracts of the American Society of Anesthesiologists, 2011.
Frey et al., 2011 Open Forum Abstracts—A Bench-Top Model: The Comparison of Leakage Occurrence Around Endotracheal Tube Cuffs in Conventional Endotracheal Tubes and Those Newly Designed to Prevent Micro-Aspiration, The Science Journal of the American Association for Respiratory Care, http://www.rcjournal.com/abstracts/2011/?id=1131204 Nov. 21, 2011.
Iwakiri et al., “Fluid Leakage Past the Tracheal Tube Cuffs: Evaluation of Seven Different Tracheal Tubes During General Anesthesia,” Oct. 17, 2011; http://www.asaabstracts.com/strands/asaabstracts/printAbstract.htm;jsessonid=ECB88FB04 (Sep. 1, 2011).
Lichtenthal et al., “Pressure Applied to Tracheal Wall by Barrel and Taper Shaped Cuffs,” Oct. 17, 2011, http://www.asaabstracts.com/strands/asaabstracts/printAbstract.htm:jsessionid=ECB88FB04 Sep. 1, 2011.
Lichtenthal, P., “Endotracheal cuff pressure: role of tracheal size and cuff volume,” Critical Care 2011, vol. 15(Suppl 1):p. 147 (DOI: 10.1186/cc9567) S52-S53.
Lichtenthal, P., “Pressure Distributions in Barrel and Taper Shaped Cuffs”, 2011.
Madjdpour et al., “Comparison of air-sealing characteristics of tapered- vs. cylindrical-shaped high-volume, low-pressure tube cuffs,” ACTA Anaesthesiologica Scandinavica DOI: 10.1111/j.1399-6576.2011.02542.x.
Mulier et al., Evaluation of Silent Aspiration in Morbid Obese Patients during Laparoscopic Gastric Bypass Surgery, Oct. 17, 2010; http://www.asaabstracts.com/strands/asaabstracts/printAbstract.htm:jsessionid=C1C176AE . . . Aug. 4, 2010.
Zanella et al., “Fluid leakage across tracheal tube cuff, effect of different cuff material, shape, and positive expiratory pressure: A Bench-top Study,” Intensive Care Med (2011) 37:343-347 DOI 10.1007/s00134-010-2106-z.
501K Summary (Revised) May 9, 2011 [sic] May 12, 2012.
Bassi et al., [Poster Board # D98] “An In-Vitro Safety Assessment of Endotracheal Tube High-Volume Low-Pressure Cuffs,” [Publication p. A1698]—https://cms.psav.com/cPaper2012/myitinerary/day.html Jun. 25, 2012.
Harayama et al., [Poster Board # D100] Effect of Different Tracheal Tube for Fluid Leakage Across the Cuff: A Bench-Top Study, [Publication p. A1700] Am J Respir Crit Care Med 185;2012:A1700.
Shiotsuka et al., “A quantitative evaluation of fluid leakage around a polyvinyl chloride tapered endotracheal tube cuff using an in-vitro model,” HSR Proceedings in Intensive Care and Cardiovascular Anesthesia 2012; 4(3): 169-175.
Tsuboi et al., “The TaperGuardTM Endotracheal Tube Intracuff Pressure Increase Is Less Than That of the Hi-LoTM Tube During Nitrous Oxide Exposure: A Model Trachea Study,” www.anesthesia-analgesia.org; Anesth Analg 2012;00:00-00.
Bassi et al., “An in Vitro Study to Assess Determinant Features Associated with Fluid Sealing in the Design of Endotracheal Tube Cuffs and Exerted Tracheal Pressures,” Critical Care Medicine, Feb. 2013, vol. 41, No. 2.
Bowton et al., “The Impact of Hospital-Wide Use of a Tapered Cuff Endotracheal Tube on VAP Incidence,” Respiratory Care Paper in Press. Published on Feb. 19, 2013 as DOI:10.4187/respcare.02278.
D'Haese et al., “Assessment of intraoperative microaspiration: does a modified cuff shape improve sealing?”, ACTA Anaesthesiologica Scandinavica DOI: 10.1111/aas.12119 (2013).
Lau et al., “Benchtop Study of Leakages Across the Portex, TaperGuard and Microcuff Endotracheal Tubes Under Simulated Clinical Conditions,” This article was published on Jul. 22, 2013 at <www.hkmj.org> Hong Kong Medical Journal; DOI: 10.12809/hkmj133930.
EP13005021.4 Notice of Publication dated Jan. 7, 2014.
EP13005021.4 Extended Search Report dated Jan. 8, 2014.
EP13005021.4 Response to Extended European Search Report dated Jul. 28, 2014.
EP 07 795 68 Examination Report dated Oct. 25, 2013.
EP 07 795 68 Response to Examination Report dated Feb. 26, 2014.
File History of U.S. Appl. No. 14/137,241, filed Dec. 20, 2013.
Jul. 18, 2016 Extended Search Report for EP Application No. 16152251.1.
Extended European Search Report for European Application No. 16152251.1 dated Jul. 18, 2016; 5 pgs.
Related Publications (1)
Number Date Country
20160175549 A1 Jun 2016 US
Continuations (4)
Number Date Country
Parent 14703525 May 2015 US
Child 15057891 US
Parent 14137241 Dec 2013 US
Child 14703525 US
Parent 13612397 Sep 2012 US
Child 14137241 US
Parent 11472733 Jun 2006 US
Child 13612397 US